Our Partnerships

The Company’s strategy of Acquire, Prepare, Commercialise is built on partnerships and academic relationships. Established from the Institute of Cancer Therapeutics (ICT) at the University of Bradford, Incanthera retains its active involvement and discussion with the evolution of technologies from the ICT and has an exclusive Pipeline Agreement offering first right to all oncology IP originating from the ICT.

Similarly, Incanthera draws on strengths of its academic and commercial relationships to prepare technologies for commercialisation at the earliest opportunity, minimising risk for shareholders and securing further investment into the Company. Incanthera’s first License Deal was signed in 2017, with current lead product Sol, its skin cancer formulation, in active discussions towards a potential commercial partnership.